Nagasawa M, Iino Y, Koibuchi Y, Andoh T, Morishita Y
Second Department of Surgery, Gunma University School of Medicine, Maebashi, Gunma 371-8511, Japan.
Oncol Rep. 2001 May-Jun;8(3):543-6. doi: 10.3892/or.8.3.543.
The effect of a combined therapy of medroxyprogesterone acetate (MPA) and 5-fluorouracil (5-FU) on tumor size, pyrimidine nucleoside phosphorylase (PyNPase) activity, and thymidylate synthetase (TS) activity was examined in Sprague-Dawley (SD) rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. MPA augmented the antitumor activity of 5-FU and protected against body weight-loss due to 5-FU administration. PyNPase activity of both the MPA group and the MPA+5-FU group tended to increase compared with that of the 5-FU alone group. TS inhibition levels in the MPA+5-FU group tended to increase compared with those in the 5-FU alone group. These results indicate that MPA tended to augment antitumor activity of 5-FU and to reduce the side effects caused by 5-FU.
在7,12-二甲基苯并[a]蒽(DMBA)诱导的乳腺肿瘤的斯普拉格-道利(SD)大鼠中,研究了醋酸甲羟孕酮(MPA)和5-氟尿嘧啶(5-FU)联合治疗对肿瘤大小、嘧啶核苷磷酸化酶(PyNPase)活性和胸苷酸合成酶(TS)活性的影响。MPA增强了5-FU的抗肿瘤活性,并防止因给予5-FU而导致的体重减轻。与单独使用5-FU的组相比,MPA组和MPA + 5-FU组的PyNPase活性均有升高趋势。与单独使用5-FU的组相比,MPA + 5-FU组的TS抑制水平有升高趋势。这些结果表明,MPA倾向于增强5-FU的抗肿瘤活性,并减少由5-FU引起的副作用。